Can you take NAC (N-acetyl cysteine) and Glutathione (liposomal / IV / S-acetyl) together?

The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

Rankings / Comparisons

NAC (N-acetyl cysteine) vs Glutathione (liposomal / IV / S-acetyl)

Precursor (NAC) vs direct supplementation (glutathione) — bioavailability, evidence, and which actually raises tissue glutathione.

Reviewed by Read Off Label · How we grade

Score comparison

NAC (N-acetyl cysteine) has the higher descriptive composite (B+, 7.1/10) compared with Glutathione (liposomal / IV / S-acetyl) (B, 6.4/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

NAC (N-acetyl cysteine)

B+ 7.1/10

aka Acetylcysteine, Mucomyst

Evidence: Moderate (psychiatric — OCD, trichotillomania, bipolar adjunct; PCOS, fertility; chronic bronchitis); Weak (generic 'detox' use); Strong (acetaminophen/APAP overdose antidote; COPD exacerbations; contrast-induced nephropathy mixed) (6/10)
Benefit: Moderate (5/10)
Risk: Low (GI upset; rotten-egg smell characteristic; bronchospasm with inhaled form) (9/10 safety)
Legality: Rx (IV for APAP overdose; Mucomyst); OTC supplement (restored after FDA 2022 decision not to pursue enforcement action after 2020 warning letters)
Dose / route context: 600-1800 mg/day PO divided; higher for acute liver protection
Class: Prescription
Last reviewed: Aug 18, 2026

Read Off Label grades NAC (N-acetyl cysteine) as B+ (7.1/10) based on moderate evidence, moderate benefit magnitude, and a low-risk safety profile.

Core component of the GlyNAC longevity combination (with glycine).

Studied, labeled, or reported-use context: 600-1800 mg/day PO divided; higher for acute liver protection — Rx (IV for APAP overdose; Mucomyst); OTC supplement; not individualized guidance.

What it is

Core component of the GlyNAC longevity combination (with glycine). Human studies report respiratory and glutathione-related effects; clinical outcome evidence varies by indication and does not substantiate broad "detox" claims. Used medically IV for acetaminophen overdose. FDA sent warning letters to Amazon sellers in 2020 claiming NAC was an unapproved drug — triggering industry litigation — then issued a 2022 final rule backing off enforcement, and NAC remains widely sold. Can cause transient nausea at high doses. A 2026 randomized trial in 60 non-diabetic adults with metabolic-dysfunction-associated steatotic liver disease (MASLD) gave 2,400 mg/day for 12 weeks on top of lifestyle advice and found nothing: no difference against lifestyle alone in oxidative stress (malondialdehyde), insulin resistance (HOMA-IR, fasting insulin, leptin), or liver steatosis and fibrosis on FibroScan. HDL rose in the NAC arm and triglycerides fell in the control arm. NAC was safe and well tolerated. The trial was open-label, which limits it, but it is a clean null for the hepatoprotective claim at a high dose and is worth weighing against the more positive NASH literature.

Mechanism

Cysteine prodrug; replenishes glutathione (rate-limited by cysteine availability); mucolytic via disulfide bond reduction; glutamate modulation in brain; anti-inflammatory; FDA-approved for acetaminophen overdose and as mucolytic

Full NAC (N-acetyl cysteine) review →

Glutathione (liposomal / IV / S-acetyl)

B 6.4/10

Evidence: Weak-Moderate (liposomal/oral supplementation — bioavailability issues, modest systemic increases); Strong (IV in APAP overdose and clinical tox) (4.5/10)
Benefit: Varies (5/10)
Risk: Low (rare sulfur GI issues; IV rare hypersensitivity) — but the IV route adds compounding-pharmacy sterility risk that the oral forms do not carry; see the Aug 2026 Class I recall in Notes (9/10 safety)
Legality: OTC (oral forms); off-label IV (compounded)
Dose / route context: Liposomal oral 500-1000 mg/day; IV 1000-3000 mg (off-label uses)
Class: Supplement
Last reviewed: Aug 29, 2026

Read Off Label grades Glutathione (liposomal / IV / S-acetyl) as B (6.4/10) based on weak-moderate evidence, variable benefit magnitude, and a low-risk safety profile.

Standard oral glutathione has poor bioavailability (broken down in GI).

Studied, labeled, or reported-use context: Liposomal oral 500-1000 mg/day; IV 1000-3000 mg (off-label uses) — OTC (oral forms); off-label IV; not individualized guidance.

What it is

Standard oral glutathione has poor bioavailability (broken down in GI). Liposomal and S-acetyl glutathione claim better absorption with supporting but not overwhelming data. NAC is a different precursor strategy with a distinct evidence and cost profile. IV glutathione has a robust cottage industry in biohacker clinics with limited controlled evidence beyond acute toxicology indications. **IV-route safety, Aug 2026.** Victory Medical Center Pharmacy recalled compounded injectable glutathione (200 mg/mL multi-dose vials, with ascorbic acid and benzyl alcohol) nationwide on 1 Jul 2026 after out-of-specification **bacterial endotoxin** results — microbial contamination of a supposedly sterile product. It is a **Class I** recall, the FDA's most serious category, meaning a reasonable probability of serious harm or death. The quantity is small (91 units) and the failure is the compounder's, not glutathione's, so the rating here is unchanged. It is worth recording because it is the concrete version of the risk this row already gestures at: the IV cottage industry operates through compounding pharmacies whose sterility assurance is not the same as a licensed manufacturer's, and an endotoxin failure in an intravenous product is a materially different hazard from a capsule that does not absorb well.

Mechanism

Primary intracellular antioxidant; tripeptide (glutamate-cysteine-glycine); reduced (GSH) and oxidized (GSSG) forms; phase II conjugation (glutathione-S-transferase) for xenobiotic elimination

Full Glutathione (liposomal / IV / S-acetyl) review →

Common questions

How do the evidence profiles of NAC (N-acetyl cysteine) and Glutathione (liposomal / IV / S-acetyl) compare?: NAC (N-acetyl cysteine) has the higher descriptive composite (B+, 7.1/10) compared with Glutathione (liposomal / IV / S-acetyl) (B, 6.4/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between NAC (N-acetyl cysteine) and Glutathione (liposomal / IV / S-acetyl)?: Precursor (NAC) vs direct supplementation (glutathione) — bioavailability, evidence, and which actually raises tissue glutathione.
Can you take NAC (N-acetyl cysteine) and Glutathione (liposomal / IV / S-acetyl) together?: The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.